Clinical trial

Gut Microbiome Components Predict Response to Neoadjuvant Therapy in HER2-positive Breast Cancer Patients : A Prospective Study

NCT05444647

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2022-07-01

PhaseN/A

Study timeline

Study start (estimated)2022-07-01Date precision: month

Registry last updated2022-07-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

stool and blood collectionPROCEDURE

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05444647 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.